Please assess the completion status of the following clinical trial:

Trial Title: SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age ≥ 18 ≤ 60 years~* Allergic rhinitis/rhinoconjunctivitis related to birch pollen with or without concomitant mild to moderate persistent asthma~* FEV1 \> 70% for patients with a history of asthma, FEV \> 70% or PEF \> 80% for patients without a history of asthma~* A positive SPT (mean wheal diameter ≥ 3mm compared to negative control and negative control should be negative) for birch pollen assessed within~  1 year before randomization.~* Positive serum specific anti-birch IgE-test (\> 0.7 U/mL)~* A positive TNPT for birch pollen at screening (Lebel score ≥ 6) at~  * 10,000 AU/mL~Exclusion Criteria:~* Patients with (expected) clinically relevant symptoms during the course of the trial due to concomitant sensitization i.e. positive SPT (mean wheal diameter ≥ 3mm) to allergens other than birch pollen~* Patients sensitized to pets should not be included if they are regularly exposed to pets and are symptomatic upon exposure to pets~* Completed immunotherapy (SCIT or SLIT) with birch pollen allergens within the past 5 years~* Completed unsuccessful specific immunotherapy in the past~* Vaccination within one week before start of therapy or during the initiation phase~* Anti-IgE therapy within the 6 months prior to inclusion and during the study~* Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs~* Active malignancies or any malignant disease during the previous 5 years~* Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases, or haematological disorders~* Active inflammation or infection of the target organs (nose, eyes or lower airways) at the start of the study~* Moderate to severe nasal obstructive diseases that preclude a TNPT (septal deviation, nasal polyps, recent nasal surgery, etc.)~* Diseases with a contraindication for the use of Adrenaline (e.g. hyperthyroidism, glaucoma)~* Use of systemic steroids within 4 weeks before start of the study and during the study~* Treatment with systemic and local β-blockers~* Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study~* Pregnancy, lactation or inadequate contraceptive measures for women of child-bearing age (adequate contraceptive measures will be the use of a contraceptive device or -pill)~* Alcohol, drug or medication abuse within the past year~* Any clinically significant abnormal laboratory parameter at screening~* Lack of cooperation or compliance~* Severe psychiatric, psychological, or neurological disorders~* Patients who are employees of the institution or 1st grade relatives or partners of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- SUBLIVAC FIX Birch 0 AUN/ml (Type: PLACEBO_COMPARATOR): None
- SUBLIVAC FIX Birch 3,333 AUN/ml (Type: ACTIVE_COMPARATOR): None
- SUBLIVAC FIX Birch 10,000 AUN/ml (Type: ACTIVE_COMPARATOR): None
- SUBLIVAC FIX Birch 20,000 AUN/ml (Type: ACTIVE_COMPARATOR): Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
- SUBLIVAC FIX Birch 40,000 AUN/ml (Type: ACTIVE_COMPARATOR): Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee

Based on this trial design, predict the completion outcome and termination type (if applicable).